Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

6.840 -0.010 (-0.15%)

Official Closing Price Updated: 4:15 PM EDT, May 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,316,081
Open	6.630
Bid (Size)	6.700 (5,000)
Ask (Size)	6.980 (100)
Prev. Close	6.850
Today's Range	6.010 - 6.867
52wk Range	4.930 - 16.45
Shares Outstanding	33,197,018
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile ↗

Today 2:07 EDT

Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory...

Via MarketBeat

Which stocks are experiencing notable movement on Thursday? ↗

May 07, 2026

Via Chartmill

Performance

YTD	-31.9%	-31.9%
1 Month	-52.2%	-52.2%
3 Month	-35.5%	-35.5%
6 Month	-1.0%	-1.0%
1 Year	-20.6%	-20.6%

More News

Top stock movements in today's session. ↗

May 07, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

May 07, 2026

Via Chartmill

Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure ↗

May 07, 2026

Via Chartmill

Which stocks are moving before the opening bell on Thursday? ↗

May 07, 2026

Via Chartmill

Entrada Therapeutics Reports First Quarter 2026 Financial Results

May 07, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

May 07, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

May 06, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 02, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

February 17, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

February 04, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

January 08, 2026

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 17, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 04, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

Via The Motley Fool

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

Via The Motley Fool

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

November 06, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

October 28, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

September 05, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Entrada Therapeutics, Inc. - Common Stock publicly traded?

Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?

Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?

The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market

What is the current price of Entrada Therapeutics, Inc. - Common Stock?

The current price of Entrada Therapeutics, Inc. - Common Stock is 6.840

When was Entrada Therapeutics, Inc. - Common Stock last traded?

The last trade of Entrada Therapeutics, Inc. - Common Stock was at 05/08/26 04:15 PM ET

What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?

The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 227.07M

How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?

Entrada Therapeutics, Inc. - Common Stock has 227M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433